Program in Details

Print this page

Day 1 (Thursday, November 26, 2026)
Time Changjo Room 1 (4F) Changjo Room 2 (4F) Miraero Room 1 (3F)
14:00-15:30 Symposium 1.
Optimizing Obesity Care: From Precision Prediction to Clinical StrategyChair(s): Oh, Sang Woo (Dongguk University, Korea), Lee, Kayoung (Inje University, Korea)
AIAARO Symposium.
Changing Paradigms in Obesity ManagementChair(s): Kim, Young-Sang (CHA University, Korea), Makkar, Brij Mohan (Dr Makkar's Diabetes and Obesity Centre, India)
Oral Presentation 1Chair(s): Kao, Hsiang-Han (China Medical University Hospital, Taiwan), Kwon, Yu Jin (Yonsei University, Korea)
14:00-14:25 Who Responds Best? Genetics of Weight Loss and Side Effects with Incretin-Based TherapyKo, Hae-Jin (Kyungpook National University, Korea) Prescribing Anti-obesity Medications – Guidelines and ConsiderationsChavda, Vipul (Rudraksha Institute of Medical Sciences, RIMS, India) 14:00-14:12Anthropometric Reclassification of Obesity and Its Associations with Cardiometabolic Abnormalities and Mortality: The Dongfeng–Tongji Cohort StudyXianli Li (Huazhong University of Science and Technology, China)
14:12-14:24Preclinical and Clinical Obesity and All-Cause and Cause-Specific Mortality: A Nationwide Cohort Study in KoreaChung-woo Lee (Veterans Health Service Medical Center, Korea)
14:24-14:36Cumulative Social Determinants of Health Burden and Obesity among Family Medicine OutpatientsDohee Lee (Korea University Guro Hospital, Korea)
14:36-14:48Waist-to-Height Ratio around 0.5 as a Simple Early Screening Threshold for Adiposity-Related Risk: Cross-Sectional and Longitudinal Evidence from the Kailuan CohortZhiqiang Pu (Huazhong University of Science and Technology, China)
14:48-15:00Transportability of Fixed Body Fat Percentage Thresholds between BIA and DXA: A Paired Analysis from KNHANES 2024Eunjin Jeong (Ewha Womans University Seoul Hospital, Korea)
14:25-14:50 Safety and Tolerability of Incretin-Based TherapiesShin, Ju-Young (Seoul National University, Korea) Obesity Management Across Women’s LifecourseChawla, Purvi (Mumbai Diabetes Research Centre, India)
14:50-15:15 Evidence-Based Switching and Combination with Incretin-Based TherapyMacklin, David (University of Toronto, Canada) Future Therapies for Obesity ManagementMakkar, Brij Mohan (Dr Makkar's Diabetes and Obesity Centre, India)
15:15-15:30 Panel DiscussionPark, Kye Young (Hanyang University, Korea)
Ryu, Ha-eun (Yonsei University, Korea)
Shine, Bo-Kyoung (Donga University, Korea)
Discussion & QnA
15:30-15:50 Coffee Break
15:50-17:20 Symposium 2.
New Horizons in Cardiometabolic TherapeuticsChair(s): Que, Do Kim (Thong Nhat Hospital, Vietnam), Yoo, Soon Jib (Eulji University, Korea)
Oral Presentation 2Chair(s): Park, Woo-Jae (Chung-Ang University, Korea), Sung, Eunju (Sungkyunkwan University, Korea)
15:50-16:15 Comparing New and Conventional Approaches in Hypertension: From Endothelin to RNA-Based TherapyLee, Jong Young (Hallym University, Korea) 15:50-16:02Weight Loss the Cardiovascular Surrogate: A 73,263-Participant Trial-Level Meta-Analysis of GLP-1 Receptor AgonismMuhammad Hamza Mubarak (Universitas Islam Indonesia, Pakistan)
16:02-16:14Real-World Assessment of Visceral Fat Changes after Semaglutide Treatment: A Korean CT Scan AnalysisKyuho Kim (The Catholic University of Korea, Korea)
16:14-16:26To Study the Therapeutic Efficacy between Injectable Semaglutide & Empagliflozin as Add on Therapy over Metformin in Type 2 Diabetes Mellitus PatientsMalay Parekh (Shanaya Diabetes & Obesity Centre, India)
16:26–16:38Survodutide, a Glucagon Receptor/GLP-1 Receptor Dual Agonist, for Weight Reduction in Adults with Obesity and Type 2 Diabetes: The SYNCHRONIZE®-2 Randomized Phase 3 Clinical TrialHae-Jin Ko (Kyungpook National University School of Medicine, Korea)
16:38–16:50Efficacy and Safety of Survodutide for the Treatment of Obesity in Adults without Diabetes: Primary Results from the SYNCHRONIZE®-1 Phase 3 TrialKyoung-Kon Kim (Gachon University Gil Medical Center, Korea)
16:50-17:02Survodutide in Adults with Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease: SYNCHRONIZE®-MASLD, a Randomized, Double-Blind, Placebo-Controlled Phase 3 TrialKyungmoon Kim (Boehringer Ingelheim Korea Ltd., Korea)
16:15-16:40 From Glycemic Control to Disease Modification: Redefining Diabetosity TherapyMakkar, Brij Mohan (Dr Makkar's Diabetes and Obesity Centre, India)
16:40-17:05 Navigating the New Landscape of Lipid-Lowering Agents Beyond StatinsWi, Jin (Gachon University, Korea)
17:05-17:20 Panel DiscussionKim, Yong Hwan (CHA University, Korea)
Seo, Yu Bin (Konkuk University, Korea)
Son, Dahye (Yonsei University, Korea)
17:30- Welcome Party